PET and PET/CT in pediatric oncology

被引:79
|
作者
Jadvar, Hossein
Connolly, Leonard P.
Fahey, Frederic H.
Shulkin, Barry L.
机构
[1] St Jude Childrens Res Hosp, Div Diagnost Imaging, Memphis, TN 38105 USA
[2] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Nucl Med, Boston, MA 02115 USA
[3] Univ So Calif, Keck Sch Med, Dept Radiol, Div Nucl Med, Los Angeles, CA USA
关键词
D O I
10.1053/j.semnuclmed.2007.04.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) and FDG-PET/computed tomography (CT) are becoming increasingly important imaging tools in the noninvasive evaluation and monitoring of children with known or suspected malignant diseases. In this review, we discuss the preparation of children undergoing PET studies and review radiation dosimetry and its implications for family and caregivers. We review the normal distribution of 18F-fluorodeoxyglucose (FDG) in children, common variations of the normal distribution, and various artifacts that may arise. We show that most tumors in children accumulate and retain FDG, allowing high-quality images of their distribution and pathophysiology. We explore the use of FDG-PET in the study of children with the more common malignancies, such as brain neoplasms and lymphomas, and the less-common tumors, including neuroblastomas, bone and soft-tissue sarcomas, Wilms' tumors, and hepatoblastomas. For comparison, other PET tracers are included because they have been applied in pediatric oncology. Multiple multicenter trials are underway that use FDG-PET in the management of children with neoplastic disease; these studies should give us greater insight into the impact FDG-PET can make in their care. PET is emerging as an important diagnostic imaging tool in the evaluation of pediatric cancers. The recent advent of dual-modality PET-computed tomography (PET/CT) imaging systems has added unprecedented diagnostic capability by revealing the precise anatomical localization of metabolic information and metabolic characterization of normal and abnormal structures. The use of CT transmission scanning for attenuation correction has shortened the total acquisition time, which is an especially desirable attribute in pediatric imaging. Moreover, expansion of the regional distribution of the most common PET radiotracer, FDG, and the introduction of mobile PET units have greatly increased access to this powerful diagnostic imaging technology. Here, we review the clinical applications of PET and PET/CT in pediatric oncology. General considerations in patient preparation and radiation dosimetry will be discussed.
引用
收藏
页码:316 / 331
页数:16
相关论文
共 50 条
  • [41] Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?
    Shirou Ishii
    Daisuke Shimao
    Takamitsu Hara
    Masayuki Miyajima
    Ken Kikuchi
    Masashi Takawa
    Kensuke Kumamoto
    Hiroshi Ito
    Fumio Shishido
    [J]. Annals of Nuclear Medicine, 2016, 30 : 225 - 233
  • [42] Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?
    Ishii, Shirou
    Shimao, Daisuke
    Hara, Takamitsu
    Miyajima, Masayuki
    Kikuchi, Ken
    Takawa, Masashi
    Kumamoto, Kensuke
    Ito, Hiroshi
    Shishido, Fumio
    [J]. ANNALS OF NUCLEAR MEDICINE, 2016, 30 (03) : 225 - 233
  • [43] Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
    Buck, Andreas K.
    Herrmann, Ken
    Stargardt, Tom
    Dechow, Tobias
    Krause, Bernd Joachim
    Schreyoegg, Jonas
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (03) : 401 - 412
  • [44] Positron Emission Tomography in oncology: Present and future of PET and PET/CT
    Papathanassiou, Dimitri
    Bruna-Muraille, Claire
    Liehn, Jean-Claude
    Nguyen, Tan Dat
    Cure, Herve
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 (03) : 239 - 254
  • [45] PET imaging: implications for the future of therapy monitoring with PET/CT in oncology
    Tomasi, Giampaolo
    Rosso, Lula
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (05) : 569 - 575
  • [46] Positron emission tomography (PET) and PET/CT for guiding therapy in oncology
    Haug, A. R.
    Bartenstein, P.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (10) : 468 - 472
  • [47] Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
    Buck, Andreas K.
    Herrmann, Ken
    Stargardt, Tom
    Dechow, Tobias
    Krause, Bernd Joachim
    Schreyogg, Jonas
    [J]. JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2010, 38 (01) : 6 - 17
  • [48] PET/MR in the Assessment of Pediatric Histiocytoses A Comparison to PET/CT
    Sher, Andrew C.
    Orth, Robert
    McClain, Kenneth
    Allen, Carl
    Hayatghaibi, Shireen
    Seghers, Victor
    [J]. CLINICAL NUCLEAR MEDICINE, 2017, 42 (08) : 582 - 588
  • [49] FDG PET and PET/CT in the Management of Pediatric Lymphoma Patients
    Cheng, Gang
    Servaes, Sabah
    Alavi, Abass
    Zhuang, Hongming
    [J]. PET CLINICS, 2008, 3 (04) : 621 - +
  • [50] FDG-PET/CT and SPECT/CT in oncology
    Kim, E. Edmund
    Yang, David J.
    Wong, Franklin C.
    [J]. CURRENT MEDICAL IMAGING, 2008, 4 (01) : 63 - 69